Dr. Wohl brings extensive expertise in preclinical drug development, having established and optimized a range of animal models for malignant glioma studies
His deep commitment to advancing the treatment of primary central nervous system (CNS) tumors is reflected in his parallel engagement in both clinical and translational research.